- Home
- GNRC vs LEGN Comparison
GNRC vs LEGN Comparison
Compare GNRC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNRC
- LEGN
- Stock Information
- Founded
- GNRC 1959
- LEGN 2014
- Country
- GNRC United States
- LEGN United States
- Employees
- GNRC N/A
- LEGN N/A
- Industry
- GNRC Metal Fabrications
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- GNRC Consumer Discretionary
- LEGN Health Care
- Exchange
- GNRC Nasdaq
- LEGN Nasdaq
- Market Cap
- GNRC 6.7B
- LEGN 7.0B
- IPO Year
- GNRC 2010
- LEGN 2020
- Fundamental
- Price
- GNRC $121.10
- LEGN $31.78
- Analyst Decision
- GNRC Buy
- LEGN Strong Buy
- Analyst Count
- GNRC 21
- LEGN 13
- Target Price
- GNRC $170.68
- LEGN $79.42
- AVG Volume (30 Days)
- GNRC 794.4K
- LEGN 1.5M
- Earning Date
- GNRC 04-30-2025
- LEGN 05-13-2025
- Dividend Yield
- GNRC N/A
- LEGN N/A
- EPS Growth
- GNRC 58.27
- LEGN N/A
- EPS
- GNRC 5.74
- LEGN N/A
- Revenue
- GNRC $4,348,682,000.00
- LEGN $627,241,000.00
- Revenue This Year
- GNRC $7.27
- LEGN $65.96
- Revenue Next Year
- GNRC $7.29
- LEGN $52.55
- P/E Ratio
- GNRC $21.01
- LEGN N/A
- Revenue Growth
- GNRC 8.07
- LEGN 119.97
- 52 Week Low
- GNRC $99.50
- LEGN $29.27
- 52 Week High
- GNRC $195.94
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- GNRC 56.26
- LEGN 41.49
- Support Level
- GNRC $113.50
- LEGN $30.25
- Resistance Level
- GNRC $122.08
- LEGN $35.81
- Average True Range (ATR)
- GNRC 3.81
- LEGN 1.45
- MACD
- GNRC 1.74
- LEGN -0.18
- Stochastic Oscillator
- GNRC 93.36
- LEGN 27.58
About GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.